

The 3rd JCA-AACR Special Joint Conference Program
March 1 to 3, 2011 @Tokyo Bay Maihama Hotel Club Resort

Date	Time	Session	proposed chair person	Title	Speaker
Mar. 1st	18:00-18:10	Opening remark			
	18:10-19:30	Keynote Lecture	Dr. Lowe Dr. Sakamoto	Molecular pathology of multistage hepatocarcinogenesis	Dr. Michiie Sakamoto (Keio Univ.)
				Integrated Approaches To Cancer Gene Discovery Using Mouse Models And RNAi	Dr. Scott Lowe (Cold Spring Harbor Lab)
20:00~	Welcome Party				
Mar. 2nd	8:00-10:00	1. Pathogenic agents and Molecular epidemiology	Dr. Ploss Dr. Shimotohno	Novel targets for anti HCV drugs preventing infectious virus particle production	Dr. Makoto Hijikata (Kyoto Univ.)
				Analysis of Hepatitis C virus infection and pathogenesis in small animal models	Dr.Alexander Ploss (The Rockefeller Univ. NY)
				Direct cytopathic effects by hepatitis B virus	Dr. Yasuhito Tanaka (Nagoya City Univ.)
				Efficacy of peg-IFN/Ribavirin combination therapy in hepatitis C	Dr. Naoki Hiramatsu (Osaka Univ.)
	10:00-10:20	Coffee Break			
	10:20-11:50	2. Preneoplastic liver injury	Dr. Friedman Dr. Kaneko	Gene expression profiles of chronic viral hepatitis	Dr. Shuichi Kaneko (Kanazawa Univ.)
				Inflammation in the pathogenesis of genetic alteration leading to liver carcinogenesis	Dr. Hiroyuki Marusawa (Kyoto Univ.)
				Senescence Surveillance in Hepatocellular Carcinoma	Dr. Lars Zender (Hannover Medical School, Germany)
	11:50-12:50	Lunch & poster view			
	12:50-14:20	Poster presentation			
	14:20-15:20	2. Preneoplastic liver injury	Dr. Friedman Dr. Kaneko	Permissive effects of fibrosis and the microenvironment on HCC development	Dr. Scott L. Friedman (Mount Sinai School of Medicine, NY)
	15:20-15:40	3. Molecular carcinogenesis	Dr. Harris Dr. Aburatani	Reversible phosphorylated Smad3 signaling between tumor-suppression and tumor-carcinogenesis in chronic hepatitis C	Dr. Koichi Matsuzaki (Kansai medical Univ.)
				p53, microRNAs and senescence in human carcinogenesis	Dr. Curtis C. Harris (National Cancer Institute, MD)
Hepatocarcinogenesis in HCV infection				Dr. Kazuhiko Koike (Tokyo Univ.)	
15:40-17:10			DNA methylation alterations during multistage hepatocarcinogenesis	Dr. Yae Kanai (National Cancer Center)	
17:30-19:00	Meet-the Expert Evening (all participants)				
19:30-21:30	Banquet				
Mar. 3rd	8:00-9:00	3. Molecular carcinogenesis	Dr. Harris Dr. Aburatani	Decoding of virus-associated liver cancer genome	Dr. Tatsuhiro Shibata (National Cancer Center)
				Integrated genomic analysis of liver cancer	Dr. Hiroyuki Aburatani (Tokyo Univ.)
	9:00-10:00	4. Molecular diagnosis	Dr. Villanueva Dr. Sakamoto	HHM (Human homologue of Maid) : an important regulator to control hepatocarcinogenesis and liver fibrosis	Dr. Shuji Terai (Yamaguchi Univ.)
				Molecular pathogenesis of hepatocellular carcinoma: preliminary steps in personalized medicine	Dr. Augusto Villanueva (BCLC, Spain)
	10:00-10:20	Coffee Break			
	10:20-10:50	4. Molecular diagnosis	Dr. Villanueva Dr. Sakamoto	Development of highly sensitive assay of serum hTERT mRNA for diagnosis of hepatocellular carcinoma	Dr. Goshi Shiota (Tottori Univ.)
	10:50-11:50	5. Metastasis and stem cells	Dr. Gouon-Evans Dr. S. Tanaka	Regulation of liver cancer stem cells by polycomb group proteins	Dr. Tetsuhiro Chiba (Chiba Univ.)
				The endothelial cell niche controls the development of hepatic progenitors	Dr. Valerie Gouon-Evans (Mount Sinai School of Medicine, NY)
	11:50-12:50	Lunch & Poster view			
	12:50-13:20	5. Metastasis and stem cells	Dr. Gouon-Evans Dr. S. Tanaka	Microenvironment and stemness potentials in hepatocellular carcinoma	Dr. Shinji Tanaka(Tokyo Medical and Dental Univ.)
13:20-14:20	6. Molecular targeted therapy	Dr. Wang Dr. Ohdan	Targetting cancer stem cells defined by HCC subtypes	Dr. Taro Yamashita (Kanazawa Univ.)	
			Integrative analysis of liver cancer omic data: linking genomics and phenomics to identify novel molecular targets	Dr. Xin Wei Wang (National Cancer Institute, MD)	
14:20-14:40	Coffee break				
14:40-15:40	6. Molecular targeted therapy	Dr. Wang Dr. Ohdan	Development of ALN-VSP: an RNAi therapeutic for solid tumors	Dr. David Bumcrot (Alnylam Pharmaceuticals Inc, MA)	
			Adoptive immunotherapy for inducing anti-HCC and anti-HCV activity after liver transplantation	Dr. Hideki Ohdan (Hiroshima Univ.)	
15:40-15:50	Closing remark				